Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

https://doi.org/10.1053/snuc/2002.31025Get rights and content

Fifty patients with somatostatin receptor-positive tumors were treated with multiple doses of [111In-diethylenetriamine pentaacetic acid0]octreotide. Forty patients were evaluable after cumulative doses of at least 20 GBq up to 160 GBq. Therapeutic effects were seen in 21 patients: partial remission in 1 patient, minor remissions in 6 patients, and stabilization of previously progressive tumors in 14 patients. Our results thus underscore the therapeutic potential of Auger-emitting radiolabelled peptides. The toxicity was generally mild bone marrow toxicity, but 3 of the 6 patients who received more than 100 GBq developed a myelodysplastic syndrome or leukemia. Therefore, we consider 100 GBq as the maximal tolerable dose. With a renal radiation dose of 0.45 mGy/MBq (based on previous studies) a cumulative dose of 100 GBq [111In-DTPA0]octreotide will lead to 45Gy on the kidneys, twice the accepted limit for external beam radiation. However, no development of hypertension, proteinuria, or significant changes in serum creatinine or creatinine clearance were observed in our patients including 2 patients who received 106 and 113 GBq [111In-DTPA0]octreotide without protection with amino acids, over a follow-up period of respectively 3 and 2 years. These findings show that the radiation of the short-range (maximal 10 microns) Auger electrons originating from the cells of the proximal tubules is not harmful for the renal function. The decrease in serum inhibin B and concomitant increase of serum FSH levels in men indicate that the spermatogenesis was impaired.

References (41)

  • van UdenA et al.

    Imaging with octreoscan: Haste makes waste

    Eur J Nucl Med

    (1999)
  • StridsbergM et al.

    Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: Development of a specific radioimmunoassay for chromogranin A and its fragments

    J Endocrinol

    (1993)
  • GuignatL et al.

    Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma

    Br J Cancer

    (2001)
  • MillerAB et al.

    Reporting results of cancer treatment

    Cancer

    (1981)
  • MignonM

    Natural history of neuroendocrine enteropancreatic tumors

    Digestion

    (2000)
  • LarssonG et al.

    Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract

    Acta Oncol

    (1999)
  • LarssonG

    Quality of life in patients with gastrointestinal tumours

  • McCarthyKE et al.

    In situ radiotherapy with 111In-pentetreotide: Initial observations and future directions

    Cancer J Sci Am

    (1998)
  • ArnoldR et al.

    Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review

    Digestion

    (2000)
  • CorneliusA et al.

    In-111-octreotide therapy: Phase I–II trial

    J Nucl Med

    (1999)
  • Cited by (369)

    • Therapy of NET with radiolabeled SST analogs

      2022, Nuclear Medicine and Molecular Imaging: Volume 1-4
    View all citing articles on Scopus
    View full text